2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2203 Elevated beta-2 microglobulin and renal dysfunction predict poor survival in multiple myeloma

Arwa Bohra, MD, Bhavesh Mohan Lal2, Prashant Kapoor, MD3, Nelson Leung, MD4, Amie Fonder, PA-C5, David Dingli, MD, PhD6, Francis Buadi, MD7, Joselle M Cook, M.D.8, Lee Her Lee, APRN, C.N.P., D.N.P.9, Yi Hwa, DNP10, Miriam Hobbs, CNP11, Moritz Binder, MD, MPH12, Nadine Abdallah I, MD13, Rahma Warsame, MD14, Saurabh Zanwar, MBBS, MD15, Suzanne Hayman, MD16, Taxiarchis Kourelis, MD17, Wilson Gonsalves, MD18, Yi Lin Jr, MD, PhD19, Morie Gertz, MD20, Angela Dispenzieri, MD21, Vincent Rajkumar22, Shaji Kumar, MD23
1 Mayo Clinic, Rochester, United States
2 Oregon Health & Science University, Oregon, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States
18 Mayo Clinic, Rochester, United States
19 Mayo Clinic, Rochester, United States
20 Mayo Clinic, Rochester, United States
21 Mayo Clinic, Rochester, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States

Background: Beta-2 microglobulin (B2M) remains central to multiple myeloma prognostication but reflects both tumor burden and renal clearance. Updated International Myeloma Society/International Myeloma Working Group (IMS/IMWG) criteria designate B2M ≥5.5 mg/L as high risk only when creatinine is <1.2 mg/dL. We evaluated whether elevated B2M retains prognostic value in renal impairment and whether renal adjustment identifies a clinically meaningful lower-risk subgroup.

Methods: We analyzed patients with multiple myeloma treated at Mayo Clinic from 2001–2024 with baseline B2M; 4,959 had corresponding estimated glomerular filtration rate (eGFR). Renal function was classified using KDIGO stages G1–G5. Patients were grouped by diagnosis year into three treatment eras: 2001–2010, 2011–2020, and 2021–2024, reflecting the pre-RVD, RVD/lenalidomide-maintenance, and monoclonal antibody eras, respectively. Expected B2M was estimated from eGFR using the Inker equation: expected B2M=(133/eGFR)1.174. Among patients with observed B2M ≥5.5 mg/L, elevation was classified as tumor-driven when observed B2M exceeded expected B2M and renal-driven when it was less than or equal to expected B2M. Overall survival (OS) was estimated using Kaplan–Meier methods and compared using log-rank tests; patients alive at last contact were censored. For validation, 651 CoMMpass patients that had complete baseline B2M, creatinine, and cytogenetic data from exome sequencing or FISH-seq were reviewed.

Results: In the Mayo cohort (n=5,255), 1,558 patients (29.6%) had B2M ≥5.5 mg/L. Groups were denoted B2M-H/L (≥5.5/<5.5 mg/L) and Cr-H/N (≥1.2/<1.2 mg/dL). B2M-H predicted inferior OS across all eras: 39.2 vs 81.5 mo in 2001–2010 and 60.4 vs 105.4 mo in 2011–2020; in 2021–2024, OS was NR in both groups but remained inferior with B2M-H (all p<0.001).

Median OS was 101 mo for B2M-L/Cr-N, 78 mo for B2M-L/Cr-H, 56 mo for B2M-H/Cr-N, and 54 mo for B2M-H/Cr-H (overall p<0.001); survival did not differ between the two B2M-H groups (p=0.9). Among 532 patients with updated IMS/IMWG-defined high-risk cytogenetic abnormalities, median OS was shortest in the B2M-H/Cr-H group (40.2 mo), followed by comparable trend amongst B2M-L/Cr-H (58.4 mo), B2M-H/Cr-N (67.6 mo), and B2M-L/Cr-N (80.7 mo; overall p<0.001). Among IMS/IMWG low-risk patients, B2M-H reduced median OS from 105.8 to 69.6 mo, approximating the 73.5-mo OS of high-risk patients with B2M-L. Patients with both high-risk disease and B2M-H had the shortest median OS at 37.9 mo. Including all patients with B2M-H in the high-risk group increased concordance from 0.57 to 0.59. B2M-H remained associated with inferior OS across all treatment eras (all p<0.001).

Among 4,956 patients with complete KDIGO and survival data, 1,205 (24.3%), 1,967 (39.7%), 1,145 (23.1%), 366 (7.4%), and 273 (5.5%) had G1, G2, G3, G4, and G5 renal function, respectively. Median OS declined from 105 mo in G1 to 54 mo in G5 (overall p<0.001), and KDIGO stage remained prognostic within each treatment era (all p<0.001). Within KDIGO strata, B2M-H predicted inferior OS in G1 (76.3 vs 106.2 mo; p=0.006), G2 (56.0 vs 95.8 mo; p<0.001), and G3 (48.5 vs 76.6 mo; p<0.001), showed a nonsignificant trend in G4 (55.8 vs 79.2 mo; p=0.06), and did not further stratify G5 disease (p=0.8). Renal adjustment did not identify a favorable B2M-H subgroup. Among patients with B2M-H, median OS was 53.0 mo for tumor-driven and 57.1 mo for renal-driven elevation. In KDIGO G4–G5 disease, median OS was similarly poor for tumor-driven and renal-driven elevation (50.4 vs 57.1 mo; p=0.1).

In the validation cohort (n=651) among patients with IMS/IMWG-defined high-risk cytogenetics (n=158), median OS was shortest in the B2M-H/Cr-H group (n=33; 30.0 mo), followed by B2M-H/Cr-N (n=14; 70.5 mo), B2M-L/Cr-H (n=23; 71.3 mo), and B2M-L/Cr-N (n=88; 89.1 mo; overall p=0.001). Among patients without high-risk cytogenetics, median OS was shortest in the B2M-H/Cr-H group (n=76; 58.7 mo) and was not reached in the B2M-L/Cr-N (n=306) and B2M-L/Cr-H groups (n=81; overall p<0.001); only one patient was classified as B2M-H/Cr-N.

Conclusions: These findings support the prognostic value of B2M ≥5.5 mg/L as high risk irrespective of renal function while recognizing KDIGO G5 disease as a distinct adverse disease state beyond high-risk myeloma features. Patients with B2M ≥5.5 mg/L and creatinine ≥1.2 mg/dL remain high risk likely from limited use of intensified therapy in the setting of multimorbidity.
Arwa Bohra, MD: No relevant conflicts of interest to declare.